<DOC>
	<DOCNO>NCT00250796</DOCNO>
	<brief_summary>Primary Aim Determine response rate time progression combination thalidomide , interferon , octreotide patient unresectable hepatocellular carcinoma ( cancer liver ca n't treat surgically ) . Secondary Aims 1 . Determine toxicity combination population . 2 . Determine survival patient cohort treat combination . 3 . Determine percent patient hepatocellular carcinoma positive octreotide scan .</brief_summary>
	<brief_title>Trial Thalidomide , a- Interferon +/- Octreotide Patients With Unresectable Hepatocellular Carcinoma</brief_title>
	<detailed_description>The purpose study determine response rate time progression combination thalidomide , alfa interferon , octreotide ( Sandostatin LAR ) patient unresectable hepatocellular carcinoma . If patient eligible agree take part study , assign one two treatment arm depend SSR status . If SSR status positive unknown , patient receive oral dos thalidomide start 200mg day increase 800mg increment 200 per week depend tolerance . They also receive injection three time week alpha interferon monthly injection octreotide ( Sandostatin LAR ) 30 mg buttock muscle.. If patient SSR status negative , patient give subcutaneous injection octreotide ( Sandostatin LAR ) receive thalidomide alfa interferon .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Octreotide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>1 . Histologically proven diagnosis hepatocellular radiographic evidence hepatic lesion consistent hepatoma alpha feto protein &gt; 500 ng/ ml 2 . The tumor unresectable 3 . Performance status &lt; 2.0 4 . &gt; 18 year age 5 . Informed consent sign patient 6 . No previous treatment thalidomide , alpha interferon , octreotide 7 . The patient may receive previous chemotherapy either systemically via intra hepatic artery . 8 . The patient may previous surgery regional therapy intra tumoral injection alcohol , cryosurgery , radiofrequency ablation . 9 . The patient must measurable disease . 10 . If female , patient must negative pregnancy test agree fall pregnant therapy . 11 . Bilirubin &lt; 3 X ULN , AST/ALT &lt; 3 X ULN , creat &lt; 2 , ANC &gt; 1.5 , Platelet &gt; 75K 12 . Patients may symptomatic cholelithiasis .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2009</verification_date>
	<keyword>Phase II</keyword>
	<keyword>Hepatocellular carcinoma</keyword>
</DOC>